Connect with us

Hi, what are you looking for?

Wednesday, Jun 29, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

Business

Havn Life partners with non-profit TheraPsil to bring safe access to psilocybin

Project Solace is an effort to secure a safe supply of psilocybin for medical purposes and move Canada closer to legalization

Havn Life partners withnon-profit TheraPsil to bring safe access to psilocybin
Magic mushrooms in capsule form. Photo via TheraPsil

A biotechnology company and a non-profit are joining forces to bring a safe source of psilocybin to patients wanting to receive psychedelics-assisted therapy.

On Monday, Vancouver-based firm Havn Life Sciences Inc.(CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) announced a partnership with the Victoria-based non-profit TheraPsil.

Under the partnership, TheraPsil will support healthcare professionals requesting psilocybin via the Special Access Program (SAP) and get the psychedelic from Havn and other psychedelics dealers enrolled in the non-profit’s “‘Project Solace”.

The project is an effort to secure a safe supply of psilocybin for patients in need and move Canada closer to legalizing psilocybin for medical purposes. Data collected through this project will help inform regulatory improvements.

On Jan. 5, Health Canada enacted amendments to its SAP which allows patients suffering from a serious or life-threatening condition to access illicit drugs such as psychedelics for therapy when other treatments have failed or are unavailable.

In the past, patients, medical professionals and advocates have expressed confusion over the steps the agency takes to determine who gets access to psilocybin.

Victoria-based non-profit TheraPsil, has been helping patients and medical professionals access medical psilocybin.

Read more: What amendments to Canada’s restricted drug program mean for patients and practitioners

Read more: Health Canada to increase legal access to psychedelics for therapy

Read more: Canadian health professionals are limited to clinical trials to access psilocybin. Experts say that’s unethical

Read more: Canadian advocates denounce ‘flawed’ system for legal psilocybin access

HAVN Life CEO Tim Moore said the company feels well aligned with organizations like TheraPsil, who advocate for compassionate access to psilocybin-assisted psychotherapy for Canadians in medical need, as well as making strides in creating a framework for what medicalized psilocybin may look like in the near future.

“We are thrilled to participate in Project Solace, which aims to move the needle on regulatory guidelines in Canada,” he added.

Patient rights advocate and TheraPsil CEO, Spencer Hawkswell said that thousands of Canadians are in urgent need of psilocybin for medical purposes.

“Our goal with Project Solace is to make access easier for patients through Health Canada’s preferred pathway, the SAP,” Hawkswell said.

“With the support of HAVN Life, a founding member of Project Solace, patients in medical need will get streamlined access, a safe supply of psilocybin, and support from therapy teams to facilitate their treatment.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can

Canada

As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices

Culture

Punishments for possession include caning and the death penalty. Despite a global trend of reform, The Fine City remains staunch in its anti-drug stance

Analysis

While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe